DelSiTech Ltd is pleased to announce that it has been included in a recently published report by MCD Group LLC. The report, “ Ocular Drug Delivery: Market Overview, Delivery Technologies, and Partnering Opportunities” covers innovative ocular drug delivery platforms like DelSiTech Silica technology which provides many benefits such as sustained release, accurate dosing, and ease of administration. In addition, the 144 page report provides a comprehensive overview of the ocular drug delivery segment and includes detailed product and technology information, market data, DDS pipelines by therapeutic category, company profiles, and partnering opportunities.
